Alpelisib

• Impact of time of alpelisib administration, concomitant fasting and low carbohydrate diet on alpelisib toxicity and efficacy; a pilot random… Not authorised
  2025-521008-22-00 Phase II 1 country Croatian Cooperative Group For Clinical Trial Research In Oncology
• EPIK-P4: A Phase II single-arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patien… Recruiting
  2024-519960-42-00 Phase II 7 countries Novartis Pharma AG
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• A no-profit, open-label, phase II pilot study on the efficacy and safety of Alpelisib in patients with Dent 2 disease (ALPEDENT study) Recruiting
  2024-514196-17-00 Phase II 1 country Ospedale Pediatrico Bambino Gesu
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 Phase II/III 7 countries Novartis Pharma AG
• Evaluation of the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polym… Recruiting
  2022-500197-34-01 Phase II 1 country Centre Hospitalier Universitaire Dijon Bourgogne
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto… Ended
  2022-502322-41-00 Phase III 6 countries F. Hoffmann-La Roche AG
• Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended
  2022-502145-10-00 Phase III 12 countries Celcuity Inc.
• SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat… Ended
  2024-514965-20-00 Phase II 1 country BOOG Study Center B.V.
• A research study to find out if the study treatment alpelisib (BYL719) is safe for a long period of time for who has confirmed diagnosis of … Ended
  2023-508522-95-00 Phase II 3 countries Novartis Pharma AG
• A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended
  2023-509133-39-00 Phase III 16 countries Novartis Pharma AG
• A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re… Ended
  2023-508530-34-00 Phase II 6 countries Novartis Pharma AG
• A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer Ended
  2023-509511-84-00 Phase I/II 2 countries Novartis Pharma AG
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended
  2022-502372-22-01 Phase II 1 country Unicancer
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended
  2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
• Study to assess the efficacy and safety of alpelisib in combination with olaparib in participants with platinum-resistant or refractory gBRC… Ended
  2024-510782-42-00 Phase III 3 countries Novartis Pharma AG
• A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr… Ended
  2024-514611-98-00 Phase III 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• Study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patie… Ended
  2024-512050-13-00 Phase III 1 country Novartis Pharma AG
• Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended
  2024-511295-33-00 Phase II 1 country Medica Scientia Innovation Research S.L.
• Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3C… Ended
  2023-509167-24-00 Phase II 2 countries Novartis Pharma AG

Showing 1–23 of 23 trials